Reducing inappropriate antibiotic prescribing for acute respiratory tract infections using an antibiotic training and management program led by local hospitals in China
| ISRCTN | ISRCTN96892547 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN96892547 |
| Secondary identifying numbers | GD AB Trial |
- Submission date
- 31/07/2019
- Registration date
- 18/08/2019
- Last edited
- 12/12/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Antimicrobial resistance has become a serious public health issue worldwide. It is mainly caused by prescribing antibiotics to people who do not need them or prescribing the wrong kind of antibiotic for the type of infection. Acute upper respiratory tract infections (RTIs), which includes colds, sore throats, laryngitis (lost voice) and sinus infections, and lower respiratory tract infections, such as chest infections and bronchitis, are commonly treated with antibiotics, especially in primary care facilities (township hospitals and village clinics). However, antibiotics are not necessary and usually do not help clear the illness. This study aims to investigate a way of working that targets doctors, pharmacists, and other healthcare professions as well as patients to try to reduce inappropriate prescribing of antibiotics for RTIs with the help of electronic medical records (EMR) and the WeChat app in rural Guangdong, China.
Who can participate?
Healthcare staff in township hospitals and patients diagnosed with acute RTIs.
What does the study involve?
The 34 participating township hospitals in two counties of Guangdong province, China, are randomly allocated into one of two arms. The township hospitals in the control arm continue usual care according to the current national guidelines.
The township hospitals in the intervention group receive an intervention package for both healthcare staff and patients. Township hospital doctors and the village doctors will receive guidelines on the appropriate use of antibiotics, key health messages and referral suggestions in both printed and WeChat app versions during a training session. An improved electronic prescription system will help to remind township hospital doctors to prescribe antibiotics cautiously. Township hospitals will establish an antimicrobial stewardship work team to hold monthly meetings to assess doctors’ prescriptions for acute RTIs with a standard procedure using EMR and the WeChat app. Patients in the intervention group will receive educational materials about appropriate antibiotic use and will be invited to link with the township hospital WeChat public account to encourage better communication.
What are the possible benefits and risks of participating?
This study may help to reduce unnecessary antibiotic use by doctors in township hospitals, increase knowledge on antibiotic use among rural patients and their caregivers, and improve the antimicrobial stewardship and prescription behaviours of health providers. No risks are expected.
Where is the study run from?
Guangzhou Institute of Respiratory Health (China) and the University of Toronto (Canada), in collaboration with Yuebei People’s Hospital (China)
When is the study starting and how long is it expected to run for?
January 2019 to February 2024
Who is funding the study?
The study is supported by the Beijing Life Oasis Public Service Center, directly supervised by the Life Oasis Public Welfare Fund Management Committee of the China Primary Health Care Foundation.
Who is the main contact?
1. Dr. Chao Zhuo, chao_sheep@263.net/chaosheep@sina.com
2. Prof. Xiaolin Wei, xiaolin.wei@utoronto.ca
Contact information
Public
Clinical Microbiology and Infectious Diseases Department
National Clinical Research Center of Respiratory Disease
First Affiliated Hospital of Guangzhou Medical University
151 Yanjiang Road
Guangzhou
510120
China
 ORCID ID |
0000-0003-2318-3236 |
|---|---|
| Phone | +8618928868397 |
| chao_sheep@263.net |
Scientific
Division of Clinical Public Health
Institute for Health Policy
Management and Evaluation
Dalla Lana School of Public Health
University of Toronto
155 College Street
Toronto
M5T 3M7
Canada
| ORCID ID |
0000-0002-3076-2650 |
|---|---|
| Phone | +1 (0)416 978 2020 |
| xiaolin.wei@utoronto.ca |
Study information
| Study design | Interventional prospective unblinded multicentre pragmatic cluster randomized controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Cluster randomised trial |
| Study setting(s) | Hospital |
| Study type | Other |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet. |
| Scientific title | Reducing inappropriate antibiotic prescribing for acute respiratory tract infections through a comprehensive antibiotic stewardship in primary care facilities: a clustered randomised controlled trial and follow-up study in rural Guangdong, China |
| Study objectives | Current study hypothesis as of 12/02/2020: In the intervention arm, inappropriate prescribing of antibiotics for acute respiratory tract infections (RTIs) would be reduced through interventions based on a comprehensive antibiotic stewardship program for primary care facilities in rural China, as compared by usual care in the control arm. The antibiotic stewardship program consists of guideline development and training, peer review of prescriptions, improved electronic medical records (EMR) and smart app communication, and patient education. The interventions would be feasible and sustainable in rural China that to be used for future scale-up. Previous study hypothesis: In the intervention arm, inappropriate prescribing of antibiotics for acute respiratory tract infections (RTIs) would be reduced through interventions based on a comprehensive antibiotic stewardship program for primary care facilities in rural China, as compared by usual care in the control arm. The antibiotic stewardship program consists of guideline development and training, peer review of prescriptions, improved electronic medical records (EMR) and smart app communication, correct-dose dispensing in the pharmacies, and patient education. The interventions would be feasible and sustainable in rural China that to be used for future scale-up. |
| Ethics approval(s) | Current ethics approval as of 14/02/2020: 1. Approved 06/02/2020, University of Toronto Office of Research Ethics (McMurrich Building, 12 Queen’s Park Crescent West, 2nd Floor, Toronto, ON M5S 1S8 Canada; ethics.review@utoronto.ca; +1 416 946-3273), ref: 38265 2. Approved 18/11/2019, Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (29th Floor, New Building of the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong Province 510120, China; kyglkgyfyy@163.com; +86 020-83062938), ref: 2019-53 Previous ethics approval as of 12/02/2020: 1. Approved 06/02/2020, University of Toronto Office of Research Ethics, ref: 38265 2. Approved 18/11/2019, Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, ref: 2019-53 Previous ethics approval: 1. Submitted 30/07/2019, University of Toronto Office of Research Ethics 2. Submitted 30/07/2019, Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University |
| Health condition(s) or problem(s) studied | Acute respiratory tract infections, including acute upper respiratory tract infections and acute bronchitis |
| Intervention | Current interventions as of 12/02/2020: All recruited township hospitals will be stratified by county and be randomized into the intervention or control group in an overall 1:1 ratio with a 9:8 ratio within each county. The control group will continue usual care according to the current national guidelines. Treatment will be provided according to existing knowledge and antibiotics will be given at the individual clinician’s discretion. The intervention will last for 12 months followed by a 24-month follow-up during the post-intervention period. The intervention group will receive an intervention package target on both health care providers and patients including the following: For healthcare provider: 1. Improved antibiotic stewardship (AMS) in each township hospital that includes an AMS team established to determine AMS policies in the institute and an AMS working group to hold monthly peer review meetings on prescriptions for acute RTIs with a standard procedure using EMR and WeChat app 2. Operational concise guidelines for RTIs based on Chinese antibiotics use guidelines, IMCI, British Thoracic Society/ NICE guidelines, and American Association of Pediatrics guidelines covering the contents of patient symptom-based diagnostic algorithms, appropriate use of antibiotics, key health education messages and referral suggestions provided for township hospital and village doctors in both printed and WeChat app version 3. Training on operational guideline and communication skills for township hospital and village doctors and an innovatively developed program embedded in the WeChat app to monitor and review antibiotics prescribing in each township hospital 4. An improved electronic prescription system including an embedded clinical decision module to prescribe antibiotics carefully, an alarm system to suggest necessary tests, and pop-ups to recommend appropriate antibiotics when an antibiotic is needed For patient: 1. Educational materials in both printed and WeChat app versions will be provided for patients with acute RTIs 2. An invitation to link their WeChat personal accounts to the township hospital WeChat public account for better communication Previous interventions: All recruited township hospitals will be stratified by county and be randomized into the intervention or control group in an overall 1:1 ratio with a 8:9 ratio within each county. The control group will continue usual care according to the current national guidelines. Treatment will be provided according to existing knowledge and antibiotics will be given at the individual clinician’s discretion. The intervention will last for 12 months followed by a 24-month follow-up during the post-intervention period. The intervention group will receive an intervention package target on both health care providers and patients including the following: For healthcare provider: 1. An improved antibiotic stewardship (AMS) in each township hospital that includes an AMS team established to determine AMS policies in the institute and an AMS working group to hold monthly peer review meetings on prescriptions for acute RTIs with a standard procedure using EMR and WeChat app 2. Operational concise guidelines for RTIs based on Chinese antibiotics use guidelines, IMCI, British Thoracic Society/ NICE guidelines, and American Association of Pediatrics guidelines covering the contents of patient symptom based diagnostic algorithms, appropriate use of antibiotics, key health education messages and referral suggestions provided for township hospital and village doctors in both printed and WeChat app version 3. Training on operational guideline and communication skills for township hospital and village doctors, reading chest X-ray reports from radiologists and an innovatively developed program embedded in the WeChat app to monitor and review antibiotics prescribing in each township hospital 4. Improved electronic prescription system including an embedded clinical decision module to prescribe antibiotics carefully, an alarm system to suggest necessary tests, and pop-ups to recommend appropriate antibiotics when an antibiotic is needed 5. Dispensing prescription-specific doses of antibiotics in township hospital For patient: 1. Educational materials in both printed and WeChat app versions will be provided for patients with acute RTIs 2. An invitation to link their WeChat personal accounts to the township hospital WeChat public account for better communication |
| Intervention type | Behavioural |
| Primary outcome measure | Proportion of prescriptions for acute RTIs that contain any antibiotic. All primary and secondary outcomes will be collected from electronic medical records at baseline (12 months before intervention), intervention period (12 months) and long-term follow-up period (24 months after intervention). |
| Secondary outcome measures | Current secondary outcome measures as of 12/02/2020: 1. Broad-spectrum antibiotic prescription rate 2. Fluoroquinolones prescription rate 3. Prescription rate for multiple antibiotics 4. Intravenous injection antibiotic prescription rate 5. The proportion of prescriptions containing any antibiotics in the Access group of the WHO’s 2019 Essential Medicine List classification 6. The proportion of prescriptions containing any Traditional Chinese Medicines 7. The proportion of prescriptions containing any glucocorticoids 8. The average cost of a prescription 9. The average cost of a consultation Previous secondary outcome measures: 1. Broad spectrum antibiotic prescription rate 2. Prescription rate for broad spectrum antibiotics excluding amoxicillin-clavulanic acid 3. Prescription rate for multiple antibiotics 4. Intravenous injection antibiotic prescription rate 5. Prescription rate for alternative medicines 6. Average cost of a prescription All primary and secondary outcomes will be collected from electronic medical records at baseline (12 months before intervention), intervention period (12 months) and long-term follow-up period (24 months after intervention). |
| Overall study start date | 01/01/2019 |
| Completion date | 31/12/2023 |
Eligibility
| Participant type(s) | Mixed |
|---|---|
| Age group | Mixed |
| Lower age limit | 0 Years |
| Upper age limit | 75 Years |
| Sex | Both |
| Target number of participants | 34 clusters, each cluster requires prescriptions of all eligible patients (at least 100 per cluster) |
| Total final enrolment | 287128 |
| Key inclusion criteria | Healthcare professionals: 1. Physicians, pharmacists, radiologists and directors in enrolled township hospitals in two selected counties in Shaoguan City, Guangdong Province who agree to participate in the study Patient/caregivers: 1. Patients aged 0-75 years diagnosed with acute RTIs and/or their caregivers |
| Key exclusion criteria | Township hospitals: 1. Township hospitals that have participated in the pilot study Patients: 1. Non-acute RTI 2. Pneumonia 3. Chronic conditions including asthma, COPD, non-infective or non-acute disorders 4. Immunological deficiencies 5. Tuberculosis 6. Any form of cancer |
| Date of first enrolment | 01/03/2020 |
| Date of final enrolment | 28/02/2023 |
Locations
Countries of recruitment
- China
Study participating centre
Shaoguan
512000
China
Sponsor information
Hospital/treatment centre
Guangzhou Institute of Respiratory Health
National Clinical Research Center of Respiratory Disease
First Affiliated Hospital of Guangzhou Medical University
151 Yanjiang Road
Guangzhou
510120
China
| Phone | +86-20-83062888 |
|---|---|
| hysggyx@163.com | |
| Website | https://www.gyfyy.com/ |
"ROR" |
https://ror.org/00z0j0d77 |
Funders
Funder type
Other
No information available
Results and Publications
| Intention to publish date | 31/12/2024 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Available on request |
| Publication and dissemination plan | Planned academic publications include main trial results, process evaluation and economic evaluation, and a follow-up study of all participants to determine long-term effect and sustainability of interventions. Results of the follow-up study will be reported in a separate paper from the trial results. |
| IPD sharing plan | The anonymised patient level data and statistical code generated during and/or analysed during the current study will be available upon reasonable request to Prof. Xiaolin Wei (xiaolin.wei@utoronto.ca) or Dr. Chao Zhuo (chao_sheep@263.net) after all papers of this study have been published and within 5 years after the trial ended. The data can only be used for research purposes and shared with research organizations/qualified researchers. Consent for data use will be obtained during patient recruitment. Confidential agreements must be signed between applicants and local hospitals before data sharing according to local policy requirements. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 12/05/2020 | 14/05/2020 | Yes | No |
Editorial Notes
12/12/2023: The following changes were made to the trial record:
1. The total final enrolment was added.
2. The recruitment start date was changed from 01/11/2019 to 01/03/2020.
3. The recruitment end date was changed from 31/01/2020 to 28/02/2023.
4. The intention to publish date was changed from 31/03/2024 to 31/12/2024.
14/05/2020: Publication reference added.
14/02/2020: The ethics approval has been updated.
12/02/2020: The following changes have been made:
1. The recruitment start date has been changed from 01/11/2019 to 01/03/2020.
2. The recruitment end date has been changed from 31/01/2020 to 31/03/2020.
3. The overall trial end date has been changed from 31/12/2023 to 28/02/2024.
4. The study hypothesis has been updated.
5. The ethics approval has been updated.
6. The interventions have been updated.
7. The secondary outcome measures have been updated.
8. The plain English summary has been updated to reflect the changes above.
15/08/2019: Trial's existence confirmed by Beijing Life Oasis Public Service Center.
